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Abstract
Lymphangioleiomyomatosis (LAM) is a rare and progressive cystic lung condition affecting approximately 3.4–7.5/million
women, with an average lag time between symptom onset and diagnosis of upwards of 4 years. The aim of this work was to
identify altered proteins in LAM serum which may be potential biomarkers of disease. Serum from LAM patient volunteers
and healthy control volunteers were pooled and analysis carried out using quantitative 4-plex iTRAQ technology.
Differentially expressed proteins were validated using ELISAs and pathway analysis was carried out using Ingenuity Pathway
Analysis. Fourteen proteins were differentially expressed in LAM serum compared to control serum (p,0.05). Further
screening validated the observed differences in extracellular matrix remodelling proteins including fibronectin (30%
decrease in LAM, p = 0.03), von Willebrand Factor (40% reduction in LAM, p = 0.03) and Kallikrein III (25% increase in LAM,
p = 0.03). Pathway networks elucidated the relationships between the ECM and cell trafficking in LAM. This study was the
first to highlight an imbalance in networks important for remodelling in LAM, providing a set of novel potential biomarkers.
These understandings may lead to a new effective treatment for LAM in the future.
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Introduction
Lymphangioleiomyomatosis (LAM) is a progressive cystic lung
condition that affects women of child bearing age, with the
average age at diagnosis being 35 years [1]. LAM occurs
sporadically (S-LAM) in approximately 3.4–7.5/million women
but it can occur in about 30% of individuals born with tuberous
sclerosis complex (TSC), and these cases of LAM are known as
TSC-LAM [2]. There are a few known cases of LAM occurring
sporadically in males [3], as well as some males with TSC but
LAM [4] is generally a complex and multifactorial disease of
females. People with LAM can present with manifestations such as
recurrent pneumothorax, pulmonary lymphangiogenesis, dyspnea,
a chylous pleural effusion, renal angiomyolipomas and abdominal
lymphangiomyolipomas [1,5]. The severity of the condition is
underlined by the fact that 10 years post diagnosis, more than half
of all LAM patients will experience shortness of breath upon light
exercise, 20% of LAM patients will require daily oxygen
supplementation and nearly 10% of people with LAM will have
died due to the disease [6]. There is a lag time of 4 years, on
average, between symptom onset and definitive diagnosis, this is
often due to ‘disease confusion’ with other respiratory conditions
such as chronic obstructive pulmonary disease or asthma [7].
Currently, the only reliable means of diagnosis of LAM is either a
high resolution computed topography (HRCT) scan or a lung
biopsy [8]. The first official guidelines for diagnosis were published
by the European Respiratory Society (ERS) LAM task force in
2010. These state that an individual with ‘definite’ LAM will have
characteristic HRCT and a pathological biopsy or characteristic
HRCT with angiomyolipoma, chylous effusion, lymphangio-
myoma and definite or probable TSC [9]. HRCT will usually
reveal multiple thin-walled cysts and a large diffuse volume of
chylous fluid. The limitations with HRCT, although it is still the
preferred method of diagnosis, are that there exist other conditions
which mimic or are similar to LAM, especially with regard to the
presence of cysts. Currently, the only potential indicative
biomarker for LAM that exists is vascular endothelial growth
factor-D (VEGF-D); it has been found that serum levels of VEGF-
D are elevated in some patients with LAM [10]. There are
limitations with this, as it is generally only elevated in patients with
a substantial lymphatic involvement and the level of VEGF-D in
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serum is not diagnostic, thus highlighting the need for additional
sensitive biomarkers [11]. There have been no high-throughput
proteomic studies of LAM serum content compared to age and
gender matched healthy control serum previously.
In terms of treatment, the only drug therapy option for LAM is
sirolimus (marketed as rapamune) which is an FDA approved
mTORC1 (mammalian target of rapamycin complex 1) inhibitor.
Individuals with TSC have a genetic mutation of TSC 1 or TSC 2
which inherently leads to over activation of signalling via the
mTOR complex, a regulator of cell growth. Individuals with
sporadic LAM can acquire mutations of TSC 2 [7,12]. Sirolimus
has been found to reduce the size of renal angiomyolipomas and
decrease the serum levels of VEGF-D [10]. However, there are
issues with sirolimus which must be considered prior to
administration of the drug. As with other immunosuppressants,
sirolimus has some adverse haematopoietic side effects and
pulmonary toxicity [13], highlighting the need for additional
therapies for LAM.
This study is, to our knowledge, the first proteomic approach to
understanding the protein content in LAM serum. We have
utilised the addition of isobaric tags for relative and absolute
quantification (iTRAQ) of identified proteins, combined with
validation in a wider cohort and pathway analysis of those
significantly identified proteins to strengthen the initial findings.
We have identified 14 potential biomarkers for the disease and
subsequently validated the findings from pooled samples in
individual patients and healthy controls.
This study constitutes a novel manner to identify a reliable
LAM biomarker with an ultimatum to understanding disease
progression further and reduce the significant length of time
patients have to wait for a clear and conclusive diagnosis. It is also
possible that one or more of the identified proteins or the pathway
that is affected may be a direct target for treatment modulation in
LAM.
Materials and Methods
Ethics Statement
Serum was collected from LAM patients (all female) and healthy
controls (all female) according to ethical guidelines approved by
The University of Sydney Human Research Ethics Committee
and participating hospitals. All patients and volunteers gave
written informed consent. Healthy volunteers had no underlying
medical illnesses and were not receiving any medication. LAM
patients were diagnosed based on tissue biopsy results and/or
HRCT according to the ERS guidelines [14].
Patients and Serum collection
A full list of patient and healthy control characteristics can be
found in Tables S1 and S2 including age, menopausal status,
FEV1 (Forced Expiratory Volume in one second) and whether
they were taking sirolimus at the time of sampling or not. Blood
was collected into BD vacutainers serum collection tubes, 367958,
Becton and Dickinson, Sydney, New South Wales), tubes were
inverted 5 times and left to clot at room temperature for
30 minutes prior to centrifugation at 14,0006g for 10 minutes.
Serum was immediately aliquoted into 200 mL aliquots and stored
at 280uC. LAM serum samples were pooled (n= 3, mean age
40.6763.67) and an aged matched healthy control group was
pooled (n = 5, mean age 4464.04), a second LAM group of older
patients was also pooled (n = 5, mean age 6162.5) and age
matched healthy controls were also collected (n = 5, mean age
57.463.14).
For subsequent validation of individual proteins, the above
individual samples and additional serum samples from LAM
patients (total n = 18, mean age = 51.966.51) and the above
individual samples and additional healthy control samples were
analysed (total n = 12, mean age = 44.2563.89).
Immunodepletion of high-abundance proteins
The top 14 abundant human serum proteins were immunode-
pleted by High Performance Liquid Chromatography (H PLC)
from the pooled serum samples [15]. Subsequent to this, samples
underwent buffer exchange with 250 mM TEAB (triethlammo-
nium bicarbonate, pH 8.5) and 0.05% SDS (three cycles of buffer
exchange) using spin columns (Sartorius Laboratory Products,
Victoria, Australia). The protein concentration of the buffer-
exchanged sample was determined using a Direct Detect
spectrometer (Merck Millipore, Victoria, Australia) and 100 mg
of each sample was then reduced with 5 mM TCEP (tris-2
carboxyethyl phosphine) and alkylated with 10 mM MMTS
(methyl mehanethiosulfonate).
Trypsin digestion and peptide fractionation with strong
cation exchange (SCX)
The proteins were digested with sequencing grade trypsin
(Promega, Alexandria, NSW, Australia) overnight at 37uC and
labelled with one of the 4-plex iTRAQ reagents according to the
manufacturer’s instructions (AB Sciex, Victoria, Australia). The
labelled samples were cleaned and fractionated by SCX HPLC.
The dried iTRAQ labelled samples were resuspended in buffer A
(5 mM Phosphate with 25% Acetonitrile, pH 2.7). Following
sample loading and washing with buffer A, a buffer of 5 mM
phosphate, 350 mM KCl with 25% Acetonitrile, pH 2.7 was
added with concentrations increasing from 10% to 45% in
70 minutes. The eluent of SCX was collected every 2 minutes at
the beginning of the gradient and, following gradient stabilisation,
this was increased to a longer 4 minute interval.
NanoLC ESI MS/MS data acquisition
The labelled samples were injected onto a peptide trap
(Michrome peptide Captrap) for pre-concentration and subse-
quently desalted with 0.1% formic acid, 2% acetonitrile at 10 mL/
minute for 5 minutes. The peptide trap was then switched into line
with the analytical column. Peptides were eluted from the column
using a linear solvent gradient, with steps, from mobile phase A:
mobile phase B (90:10) to mobile phase A:mobile phase B (65:35),
where mobile phase A was 0.1% formic acid and mobile phase B
was 90% ACN/0.1% formic acid at 1000 nL/minute over a
90 min period. After peptide elution, the column was cleaned with
95% buffer B for 15 minutes and then equilibrated with buffer A
for 25 minutes prior to the next sample injection.
The reverse phase nanoLC eluent was subjected to positive ion
nanoflow electrospray analysis in an information dependant
acquisition mode (IDA). In IDA mode a TOFMS survey scan
was acquired (m/z 400–1500, 0.25second), with the ten most
intense multiply charged ions (counts .150) in the survey scan
sequentially subjected to MS/MS analysis. MS/MS spectra were
accumulated for 200 milliseconds in the mass range of m/z 100 to
1500 with the total cycle time being 2.3 seconds.
Data processing
The experimental nanoLC ESI MS/MS data were submitted to
ProteinPilot Version 4.2b (AB Sciex, Victoria, Australia) for data
processing, using the homo sapiens database. Data were normal-
ised for any error by bias correction using ProteinPilot. The data
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were expressed as ratios, comparing LAM groups versus healthy
controls. The detected protein threshold (unused ProtScore) was
set at larger than 1.3 (better than 95% confidence) and a protein
was considered significantly different from the healthy control
group when the p value was ,0.05.
Individual Protein Validation with ELISA
For subsequent validation of a number of the proteins identified
from the quantitative iTRAQ experiments, sandwich enzyme
linked immunosorbent assays (ELISAs) were employed. The
concentration of fibronectin was quantified in the individual
serum samples with the use of a human fibronectin ELISA kit
(EK0349) from Boster Biologicals, iScience Inc, Victoria, Aus-
tralia. Serum samples were diluted 1/10,000 and analysed
according to the manufacturer’s recommendations. The concen-
tration of von Willebrand factor (vWF) was determined in the
serum samples using a vWF human ELISA kit (Abcam, Waterloo,
Australia, ab108918), serum samples were diluted 1/100 and
assayed according to the manufacturer’s instructions. Levels of
Kallikrein III were determined by ELISA (Abcam, Waterloo,
Australia, ab1013327) with serum samples diluted 1/100 and the
levels of plasminogen were also determined by ELISA (Abcam,
Waterloo, Australia, ab108893) with dilutions of 1/20,000 and
assayed according to the manufacturer’s instructions.
Figure 1. Experimental workflow of the study. Serum was isolated from patients and healthy controls, pooled and trypsin digested prior to the
addition of 4-plex iTRAQ reagents and mass spectrometry. Validation of four significantly altered proteins was carried out using sandwich ELISAs.
doi:10.1371/journal.pone.0105365.g001
Table 1. Serum proteins showing a significant decrease in expression in LAM serum versus Healthy aged-matched controls.
Accession
Number Protein Name
Ratio: Lam (1)
versus Healthy (1)
P Value: Lam (1)
versus Healthy (1)
Ratio: Lam (2)
versus Healthy (2)
P Value: Lam (2)
versus Healthy (2 Protein Function
P02751 Fibronectin 0.044 3.8E-38 0.26 4.9E-32 extracellular matrix
organization
P04275 von Willebrand factor 0.47 2.03E-10 0.56 1.3E-06 haemostasis
P05546 Heparin cofactor 2 0.61 3.4E-07 0.8 0.0008 regulation of proteolysis
P04278 Sex hormone-binding
globulin
0.64 0.0003 0.72 0.0001 hormone transport
P00747 Plasminogen 0.77 0.001 0.78 0.007 negative regulation of
cell proliferation
P18428 Lipopolysaccharide-
binding protein
0.74 0.001 0.82 0.03 cellular response to
lipoteichoic acid
Q9UGM5 Fetuin-B 0.55 0.006 0.7 0.02 Protease Inhibitor
doi:10.1371/journal.pone.0105365.t001
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Immunohistochemistry detection of fibrnonectin, vWF
and ROS in lung tissue of LAM patients
Parrafin embedded lung tissue sections were stained for
fibronectin (Sigma, F3648), vWF (Abcam, ab6994) and reactive
oxygen species (ROS, Abcam, ab5512) with negative control
isotypes used on serial sections (Dako). Sections were imaged using
an Olympus BX60 microscope and densitometry was analysed
with ImageJ software.
Pathway Analysis
In order to model possible interactions between the identified
proteins that were significantly increased or decreased in patient
groups compared to the respective control groups, Ingenuity
Pathways Analysis (IPA) software (Ingenuity Systems, CA, USA)
was used. Interactive pathways were generated to observe direct
and indirect relationships among the significantly changed
proteins.
Statistical Analysis
The validation data were expressed as means 6 standard error
using Graph Pad Prism version 5.0 (Graph Pad Software, CA,
USA). Between group comparisons were performed using the
Mann-Whitney U- test, using a 95% confidence interval and
taking a p Value,0.05 as significant. Outliers were removed if the
relative value was more than two standard deviations from the
mean of the group.
Results
Identification of significant changes in protein content of
LAM patient serum versus healthy control serum
The experimental workflow for the iTRAQ experiments and
subsequent validation is illustrated in Fig. 1, whereby two groups
of LAM serum were each pooled (n = 3, n = 5) and complexed
with two reporter iTRAQ labels (114 and 115, respectively) and
the same was done with two groups of healthy control samples
(n = 5, n = 5) which were labelled with the reporter ions 116 and
117, respectively. The rationale for choosing two groups was that
the data generated in the first group of LAM serum could be
confirmed in a second group of LAM serum. The workflow
combined a depletion of the top 14 most abundant proteins by
HPLC, tryptic digestion and protein quantification to ensure equal
loading of each pooled sample. After determining the concentra-
tion of each pooled sample 100 mg of each sample was brought
forward for labelling and analysis.
The iTRAQ labelling ratios were used for quantification
purposes. In the first group of LAM sera -LAM (1) 243 proteins
were identified to have a fold change relative to healthy control (1)
with 238 of these being identified with at least two peptides,
whereas in the second group LAM (2) 243 proteins were found to
be different with 190 of these being identified with at least two
peptides. The proteins which were found to be significantly
different in both LAM groups compared to the healthy control
groups are listed in Table 1 (decreased proteins) and Table 2
(increased proteins). The decreased proteins included fibronectin,
the ratio of which was 0.044 in LAM (1) versus Healthy (1) and
Table 2. Serum proteins showing a significant increase in expression in LAM serum versus Healthy aged-matched controls.
Accession
Number Protein Name
Ratio: Lam (1)
versus Healthy
(1)
P Value: Lam (1)
versus Healthy (1)
Ratio: Lam (2)
versus Healthy
(2)
P Value: Lam (2)
versus Healthy (2) Protein Function
P08519 Apolipoprotein (a) 1.61 0.0008 4.12 1.22402E-07 lipid transport
P03952 Kallikrein III 4.66 0.001 1.53 0.002 proteolysis
P05154 Plasma serine protease
inhibitor
3.43 0.0004 1.44 0.001 regulation of proteolysis
Q9Y490 Talin-1 1.48 0.002 1.25 0.04 cell-cell junction assembly
Q96PD5 N-acetylmuramoyl-L-alanine
amidase
1.27 0.03 1.31 0.02 negative regulation of
natural killer cell
differentiation involved in
immune response
P06727 Apolipoprotein A-IV 1.22 0.03 1.27 0.002 regulation of cholesterol
transport
P55058 Phospholipid transfer
protein
2.59 0.04 1.78 0.013 lipid transport
doi:10.1371/journal.pone.0105365.t002
Table 3. The effect sizes of each respective group.
Mean healthy Standard deviation healthy Mean LAM Standard deviation LAM Effect size (d)
Fibronectin 34833 2828 24214 3200 0.869
Von Willebrand Factor 6254 527.7 3754 554.2 0.918
Kallikrein III 739.8 64.98 981.3 72.82 0.868
doi:10.1371/journal.pone.0105365.t003
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0.26 in LAM (2) versus Healthy (2). Other proteins identified as
being significantly decreased in both LAM groups were von
Willebrand factor (vWF), the ratio being 0.47 and 0.56 in group (1)
and group (2), respectively. Heparin cofactor 2 was identified as
significantly decreased in abundance, in both groups, (Group 1
ratio versus healthy controls was 0.61 and Group 2 was 0.8), sex-
hormone binding globulin (SHBG), plasminogen, LPS-binding
protein and Fetuin –B were also decreased.
Table 2 demonstrates proteins which were significantly in-
creased in the circulation of the LAM patient groups compared to
the healthy control group. The levels of the serine protease
Kallikrein III were also found to be significantly higher in the
LAM groups (1) and (2), 4.66 and 1.53, respectively. Table 3 lists
the proposed roles of the identified proteins which were found to
be altered in the LAM patient groups.
Validation of the iTRAQ results using ELISA and
immunohistochemistry in individual LAM patient
samples and healthy aged matched controls
Four proteins were chosen for individual validation, fibronectin,
(vWF), kallikrein III and plasminogen. The iTRAQ quantitative
results had revealed that fibronectin, vWF and plasminogen were
significantly decreased in LAM patients whereas kallikrein III was
increased. The levels of fibronectin were again observed to be
significantly reduced in the serum from a larger cohort of LAM
patients compared to healthy control samples with a mean
quantity of fibronectin found to be 2421463200 mg/mL in LAM
(n= 17) and 3483362828 mg/mL in healthy controls (n = 11,
p = 0.0377, Fig. 2A).
The effect size based on the means and standard deviations for
the two groups were calculated as previously described [16]. The
effect size (d) denotes a means of quantifying how large the
difference is between the groups. The effect size of fibronectin is
0.869 (see Table 3). An effect size is exactly equivalent to a ‘Z-
score’ of a standard normal distribution. In the case of fibronectin,
this means that the average LAM patient has a circulating
fibronectin level 0.87 standard deviations below the average
person in the control group, and hence falls below the fibronectin
level of 86% of the control group. It was found that vWF fell below
91% of the relative control group whereas kallikrein III was above
86% of the control group.
It was also found using iTRAQ-labelling techniques that the
levels of vWF were significantly reduced in LAM serum. Using
ELISA to detect and validate levels of vWF in LAM serum and
healthy control serum it was found that mean vWF in LAM was
37546554.2 u/mL (n= 15) compared to 62546527.7 u/mL in
Figure 2. Validation of identified proteins in serum from individual LAM patients and healthy controls. Serum from LAM patients
(n = 18) and age and gender matched healthy control samples (n = 12) assayed for levels of fibronectin (a), von Willebrand Factor (b), Kallikrein III (c)
and Plasminogen (d) using ELISA. * indicates P,0.05 compared to healthy controls, statistical analyses were performed using the Mann Whitney U-
test.
doi:10.1371/journal.pone.0105365.g002
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healthy controls (n = 10, p= 0.036, Fig. 2B). We also investigated
the amount of kallikrein III in the circulation of individual LAM
and healthy control samples. The ELISA results revealed that the
mean concentration of kallikrein III in LAM serum was
981.3672.82 pg/mL (n= 17), whereas the mean concentration
in the healthy control group was 739.8664.98 pg/mL (n= 12,
p = 0.036, Fig. 2C). Immunohistochemical analysis of lung
sections obtained from LAM patients and healthy control
individuals demonstrated a significant increase in the deposition
of fibronectin (p = 0.043) in LAM patients compared to healthy
control lung sections (Fig 3A and 3B). There was also an increase
in the density of positively stained areas for vWF in LAM lung
tissue compared to healthy controls (p = 0.0359, Fig 3C and 3D).
Immunohistochemical analysis for areas containing reactive
oxygen species was also performed as ROS can become increased
via kallikrein III bioavailability [17]. Lung sections from LAM
patients had significantly higher staining for ROS compared to
healthy controls (p = 0.0473, Fig 3E and 3F).
Ingenuity Pathway analysis of the identified iTRAQ
proteins
Analysis of the data using Ingenuity Pathway analysis software
enabled us to investigate the pathways and known relationships
with other proteins from the literature with the proteins we had
identified as being differentially expressed in LAM serum. The
most relevant pathway, that contained 12 of the 14 identified
proteins, was connected to cell trafficking and ECM remodelling,
Fig. 4.
Discussion
This study is the first of its kind, in that we have utilised a
modern, quantitative tool to understand and analyse the content of
LAM serum compared to healthy control serum. The data we
have presented describe 14 significantly altered proteins which
were common in two LAM patient cohorts compared to age and
gender matched healthy control groups.
It is widely recognised that patient serum is a valuable resource
for understanding what may be contributing to a dysregulated
pathway, network or mechanism in a disease state. For this reason,
this study elucidates what is significantly different between LAM
serum and that from healthy age and gender matched control
patients. We have identified a significant imbalance in the proteins
involved in ECM assembly and disassembly, the ECM being the
scaffolding which allows cellular and tissue organisation to occur
via a dynamic network of integrins, growth factors and fluids [18].
ECM disorganisation has been found to play a part in many
respiratory diseases, for example asthma [19] as well as some other
multifactorial diseases, such as cancer. In terms of LAM, it has
previously been shown that deposited levels of fibronectin are
significantly higher in lung biopsy sections from LAM patients
[20]. Fibronectin is a ubiquitous ECM glycoprotein, the circulat-
ing levels of which are essential in terms of maintaining a healthy
ECM surrounding tissues and cells. Taking our results (decreased
fibronectin in LAM serum and an increase in the deposition in
lung tissue of LAM patients) into account, combined with these
previous findings, there is an indication that there is an imbalance
existing in LAM with regard to the relationship between
circulating soluble levels of fibronectin and the deposited levels
of insoluble fibronectin in the lung.
The role of vWF is best known in terms of haemostasis, but
recently it has become evident that circulating levels of vWF can
be markers for acute respiratory distress syndrome and COPD
[21]. It has also recently emerged that lung biopsy sections from
LAM patients stain positively for deposited vWF [22]. The low
levels we have observed in LAM serum may be due to the
aggregation of vWF at the cystic regions in the lungs which was
confirmed in immunohistochemical analysis of LAM lung tissue,
Figure 3. Immuohistochemical analysis of fibronectin, von Willebrand factor and reactive oxygen species in lung tissue from LAM
patients and healthy controls. Parrafin embedded sections of lung tissue from LAM patients and age and gender matched healthy controls were
stained and analysed for fibronectin (a and b), von Willebrand factor (c and d) and reactive oxygen species (e and f) positive regions. * indicates P,
0.05 compared to healthy controls, statistical analyses were performed using the Mann Whitney U-test.
doi:10.1371/journal.pone.0105365.g003
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much the same as fibronectin deposition observed in LAM
patients. vWF can bind to endothelial and fibroblastic regions of
the ECM [23], therefore, it is possible that there is a similar
phenomenon occurring with vWF in that it is largely depositing in
the LAM cystic regions, as well as potentially in the angiomyo-
lipomas seen in LAM patients. The reduction of vWF in the
circulation combined with our finding of elevated levels of vWF on
tissue sections from LAM patients may suggest that the lower vWF
abundance in the serum is due to a more intimate association
between activated endothelial cells and the fibrotic tissue in the
lung.
Zhe and colleagues have reported that an imbalanced
plasminogen system exists in LAM, with LAM lesions showing
stronger staining for plasminogen than the surrounding, seemingly
healthy parenchyma [24]. Our findings support this, as the serum
levels of plasminogen were significantly decreased in the iTRAQ
results. It is conceivable that plasminogen has followed a similar
route to the other ECM- associated proteins which we have
identified, especially since it has previously been implicated in
LAM ECM degradation [24]. A high level of circulating
plasminogen can be indicative of risk of cardiovascular disease,
but is also a factor in tissue remodelling [25]. Two proteins in the
apolipoprotein family were identified as being significantly
increased, those being Apolipoprotein (a) (the ratio LAM (1):
healthy (1) was 1.61 and the ratio of LAM (2): healthy (2) was
4.12). Apolipoprotein (a) functions to transport high density
lipoproteins in the circulation [26]and an increase in its presence
in the serum is a factor which is known to contribute to
cardiovascular disease [27], although a recent murine study for
lung fibrosis found that administration of Apolipoprotein (a)
improved inflammation and collagen deposition [28]. It has been
found that epithelial cells lining LAM nodules reacted positively
with PE-10, an antibody that reacts with apolipoprotein (a) in type
II pneumocytes [29].
Kallikrein III, also known as ‘Prostate specific Antigen’, has long
been a biomarker for prostate cancer [17], but is also involved in
the degradation of the ECM [30]. Our finding, of increased
kallikrein III in LAM serum, further indicates that the ECM in
LAM patients is dysfunctional and imbalanced compared to the
healthy control group. Kallikrein III is a serine protease indirectly
involved in the bio-availability of insulin-like growth factor (IGF) 1
and 2 [30]. IGFs are prominent growth factors in cell proliferation
and have previously been suggested as potential mitogens involved
in LAM cell proliferation [31], however the availability of IGFs
Figure 4. Pathway analysis of proteins which were significantly changed in serum from LAM patients. Twelve out of fourteen proteins,
identified as being changed in serum from patients with LAM are part of a complex pathway involved in cell trafficking. Proteins which were
significantly altered in LAM patient serum compared to healthy controls are highlighted in red.
doi:10.1371/journal.pone.0105365.g004
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may be secondary to the abundance of kallikrein III in the
circulation [32]. Kallikrein III can also stimulate the production of
reactive oxygen species (ROS) [17]. The production and
availability of ROS is not widely studied in LAM and our results
have demonstrated intense ROS positive regions in LAM lung
tissue, but an overproduction of ROS is recognised in respiratory
diseases as a contributor to disease development, evident in
conditions such as asthma and idiopathic pulmonary fibrosis [33]).
An overproduction of ROS in the LAM lung, which may be due
to the levels of kallikrein III in the serum, could be contributing to
the cellular infiltration in LAM. ROS have been found to be
involved in the adhesion between endothelial cells and inflamma-
tory cells, most noteworthy in asthma, which can lead to bronchial
constriction [34]. Interestingly, ROS have also been found to
contribute to lymphangiogenesis, which is a key process in LAM
[22], in non-small cell lung cancer[35]. The reduction of SHBG in
LAM serum may be a factor driving the oestrogen association in
LAM. However, interestingly, a reduction of SHBG is also seen in
patients with myxedma, a condition which is a complication of
hypothyroidism and is also almost exclusive to women [36].
Patients can present with acute non pitting peripheral oedema, a
dysregulation of the lymphatic system bearing similarities to LAM.
Pathway analysis using the IPA software revealed intricate
details with regard to the feedback loops and network relationships
between the significantly altered proteins identified in this study. It
was found that 12 out of 14 of the iTRAQ identified proteins were
involved in a pathway driving cell movement and trafficking,
which is a major factor in LAM patients, emphasised by the fact
that women with LAM who have had lung transplants may see a
return of the disease and a return in lung function decline in the
newly donated donor lungs [37]. The LAM cells are found to
survive in the circulation and appear to be recruited to the lungs
(even after a lung transplant) in a manner similar to that which
occurs in a metastatic state [38].
Concluding Remarks
Our findings add to the current literature which is building a
catalogue of evidence for defective ECM organisation in LAM
patients. We have provided a dynamic list of proteins which were
significantly altered in the circulation of LAM patients, three of
which we validated in individual LAM and healthy control
samples in order to strengthen the mass spectrometry findings.
The strength of this study is that we have validated, in a larger
population, four of the proteins (similar to other serum screening
studies [39]) identified to differ in two separate LAM cohorts
subsequent to screening with iTRAQ labels.
The panel of results does have some limitations in that, due to
the rarity of the disease, we had a limited number of patient
samples available for the study. We used serum from 18 LAM
patients altogether in this study. Eight samples were used initially
for the mass spectrometry; subsequent to this samples were
acquired from additional patient volunteers for our validation
studies. For a condition that occurs in only 3.4–7.5/million
women we feel that these numbers provide a robust representative
of the disease. However the limitation of small numbers is
attenuated by the fact that the commonalities we report here were
identified in two different LAM serum sample pools before
verification in a larger cohort analysing individual patients
separately.
The data presented in this manuscript have the potential to
assist in further reducing the long lag time currently observed in
diagnosing LAM patients, as well as understanding the disease
mechanisms and ultimately treating this multifactorial and
devastating disease.
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